Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanologica AB ( (SE:NICA) ) just unveiled an announcement.
Nanologica AB, headquartered in Södertälje and listed on Nasdaq Stockholm, focuses on advanced purification consumables for peptide-based pharmaceuticals and operates contract manufacturing through its Syntagon unit. The company targets a global niche market driven by increasing demand for diabetes and obesity treatments, leveraging its expertise in small molecules, peptides, and complex compound purification.
The company has completed registration of previously resolved share issues, resulting in a substantial increase in its share count and share capital during April. The total number of shares and votes now stands at 328,769,842, up from 119,973,600, which significantly strengthens Nanologica’s capital base and may influence its ownership structure and financial flexibility going forward.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced chromatographic consumables to pharmaceutical manufacturers. Its products are tailored for purification of peptide drugs, including insulin and GLP-1 analogues, aiming to boost productivity and cut costs for drug makers in a growing global niche tied to rising diabetes and obesity treatments. The group also includes Syntagon, a contract manufacturer specializing in small molecules and peptides, with particular strength in purification and analysis of complex pharmaceutical compounds.
Average Trading Volume: 2,242,336
Technical Sentiment Signal: Sell
Current Market Cap: SEK58.21M
Find detailed analytics on NICA stock on TipRanks’ Stock Analysis page.